High-risk surgically resected pediatric melanoma and adjuvant interferon therapy This study was reported as a poster at the 2003 ASPHO meeting in Seattle, Washington.
dc.contributor.author | Chao, Mwe Mwe | en_US |
dc.contributor.author | Schwartz, Jennifer L. | en_US |
dc.contributor.author | Wechsler, Daniel S. | en_US |
dc.contributor.author | Thornburg, Courtney D. | en_US |
dc.contributor.author | Griffith, Kent A. | en_US |
dc.contributor.author | Williams, James A. | en_US |
dc.date.accessioned | 2006-05-17T14:49:06Z | |
dc.date.available | 2006-05-17T14:49:06Z | |
dc.date.issued | 2005-05 | en_US |
dc.identifier.citation | Chao, Mwe Mwe; Schwartz, Jennifer L.; Wechsler, Daniel S.; Thornburg, Courtney D.; Griffith, Kent A.; Williams, James A. (2005)."High-risk surgically resected pediatric melanoma and adjuvant interferon therapy This study was reported as a poster at the 2003 ASPHO meeting in Seattle, Washington. ." Pediatric Blood & Cancer 44(5): 441-448. <http://hdl.handle.net/2027.42/39136> | en_US |
dc.identifier.issn | 1545-5009 | en_US |
dc.identifier.issn | 1545-5017 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/39136 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15468307&dopt=citation | en_US |
dc.description.abstract | Background Pediatric patients with high-risk surgically resected melanoma are at risk for relapse, yet little is known about these young patients and how they tolerate high-dose interferon therapy. Procedure We reviewed medical records of patients (≤18 years) with high-risk melanoma referred to the University of Michigan Pediatric Hematology-Oncology service between January 1989 and July 2003. Results Fourteen patients were identified with high-risk resected melanoma. The median age at diagnosis was 8.5 years. The median time to establish diagnosis was 9 months. Primary lesions were diagnosed as unequivocal melanoma, atypical epithelioid melanocytic proliferations, or atypical Spitz tumor with indeterminate malignant potential. Twelve patients had a positive sentinel lymph node (SLN) biopsy or a palpable regional lymph node and underwent regional lymph node dissection (LND). Two patients with unequivocal melanoma with Breslow depth >4 mm had negative SLN biopsies. Twelve patients received adjuvant high-dose interferon. The following toxicities were observed: constitutional symptoms, gastrointestinal symptoms, depression or neuropsychiatric symptoms, myelosuppression, elevated AST or ALT, hypothyroidism, and hypertension. Grade 3 or 4 toxicities were uncommon with exception of neutropenia, resulting in modification of therapy in one patient. All patients are alive and free of disease at follow-up (median 24.5 months). Conclusions Invasive melanoma can occur in very young children. Despite early signs of malignancy, there is often a delay in diagnosis. Histologically, diagnosis may be difficult because of overlap with Spitz nevi. Pediatric patients tolerated adjuvant high-dose interferon well and may be less likely than adults to require therapy modification secondary to toxicities. © 2004 Wiley-Liss, Inc. | en_US |
dc.format.extent | 109341 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | High-risk surgically resected pediatric melanoma and adjuvant interferon therapy This study was reported as a poster at the 2003 ASPHO meeting in Seattle, Washington. | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pediatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pediatric Hematology-Oncology, University of Michigan Health System, Ann Arbor, Michigan ; Department of Pediatrics, Division of Pediatric Hematology-Oncology, University of Michigan Health System, 1500 East Medical Center Drive, CCGC 4410, Ann Arbor, MI 48109-0936. | en_US |
dc.contributor.affiliationum | Department of Dermatology, University of Michigan Health System, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Pediatric Hematology-Oncology, University of Michigan Health System, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Pediatric Hematology-Oncology, University of Michigan Health System, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Biostatistics, University of Michigan Health System, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Pediatric Hematology-Oncology, University of Michigan Health System, Ann Arbor, Michigan | en_US |
dc.identifier.pmid | 15468307 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/39136/1/20168_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/pbc.20168 | en_US |
dc.identifier.source | Pediatric Blood & Cancer | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.